|
Dr. Chris Miller is the Chairman of the Board of Geonox Corporation and serves as Chief Scientific Officer. Geonox is a biopharmaceutical company dedicated to the development of nitric oxide gas (gNO) therapies and technologies in the areas of immunology, cancer and infectious diseases. Dr. Miller was the visionary founder of Pulmonox Research and Development Corporation (1993), a highly successful leading-edge biotech company. Dr. Miller’s leadership has resulted in establishing Pulmonox as a world leader in nitric oxide platform technology. Dr. Miller has a doctorate in experimental medicine from the University of British Columbia, Canada, Faculty of Medicine. His thesis evaluated the use of gaseous nitric oxide (gNO) as antibacterial agent for respiratory tract infections and surface wound infections. Dr. Miller, has authored over 20 papers in peer review publications and has five issued patents with 14 pending. In 2004, he received the prestigious Jimmy Schultz Award for his dedication to improving patient care through research and innovative use of respiratory care technology. | 